Assessment of the budgetary impact of an emicizumab therapy introduction for patients with severe haemophilia A without inhibitor
Copyright © 2022 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved..
Since March 2019, émicizumab is indicated for the treatment of patients with severe haemophilia A without inhibitor. This therapy's price amounts approximately to €33 600 per 4 weeks for a 70kg patient which represents about two times more than a factor VIII concentrates treatment's price. This study aims to assess the budgetary impact for the French Health Insurance of an émicizumab therapy introduction for patients with severe haemophilia A without inhibitor. It was an observational, retrospective, and monocentric study. Every severe haemophilia A without inhibitor patient over 18 years old followed at the Cochin Hospital haemophilia treatment centre who received émicizumab from June 2020 and for at least one year have been included. The budgetary impact was estimated by comparing the total costs of patient care the year before versus the year after émicizumab initiation. Total costs of patient care included prices of i) treatments consumed, ii) consultations with specialist physicians, iii) hospitalizations and iv) imaging procedures. Thirty-eight patients were included. The total cost of patient care increased significantly the year after émicizumab introduction (P < 0.0001). On average, this cost was estimated at €537 887 ± €137 139 per patient whereas it was at €151 442 ± €94 708 the year before. While costs of physician consultations increased, no significant difference has been reported about hospitalizations and imaging costs. Over a one-year period, émicizumab therapy significantly increased the total costs of patient care. It is mostly caused by the drug price itself.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
|---|---|
| Enthalten in: |
Annales pharmaceutiques francaises - 81(2023), 3 vom: 01. Mai, Seite 529-537 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Évaluation de l’impact budgétaire de l’introduction d’un traitement par émicizumab chez des patients atteints d’hémophilie A sévère congénitale sans inhibiteur |
|---|
| Beteiligte Personen: |
Oka, G [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.04.2023 Date Revised 24.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pharma.2022.11.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348889976 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348889976 | ||
| 003 | DE-627 | ||
| 005 | 20231226041332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.pharma.2022.11.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM348889976 | ||
| 035 | |a (NLM)36375527 | ||
| 035 | |a (PII)S0003-4509(22)00144-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Oka, G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessment of the budgetary impact of an emicizumab therapy introduction for patients with severe haemophilia A without inhibitor |
| 246 | 3 | 3 | |a Évaluation de l’impact budgétaire de l’introduction d’un traitement par émicizumab chez des patients atteints d’hémophilie A sévère congénitale sans inhibiteur |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.04.2023 | ||
| 500 | |a Date Revised 24.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Since March 2019, émicizumab is indicated for the treatment of patients with severe haemophilia A without inhibitor. This therapy's price amounts approximately to €33 600 per 4 weeks for a 70kg patient which represents about two times more than a factor VIII concentrates treatment's price. This study aims to assess the budgetary impact for the French Health Insurance of an émicizumab therapy introduction for patients with severe haemophilia A without inhibitor. It was an observational, retrospective, and monocentric study. Every severe haemophilia A without inhibitor patient over 18 years old followed at the Cochin Hospital haemophilia treatment centre who received émicizumab from June 2020 and for at least one year have been included. The budgetary impact was estimated by comparing the total costs of patient care the year before versus the year after émicizumab initiation. Total costs of patient care included prices of i) treatments consumed, ii) consultations with specialist physicians, iii) hospitalizations and iv) imaging procedures. Thirty-eight patients were included. The total cost of patient care increased significantly the year after émicizumab introduction (P < 0.0001). On average, this cost was estimated at €537 887 ± €137 139 per patient whereas it was at €151 442 ± €94 708 the year before. While costs of physician consultations increased, no significant difference has been reported about hospitalizations and imaging costs. Over a one-year period, émicizumab therapy significantly increased the total costs of patient care. It is mostly caused by the drug price itself | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Budgetary impact | |
| 650 | 4 | |a Emicizumab | |
| 650 | 4 | |a Hémophilie A sévère | |
| 650 | 4 | |a Impact budgétaire | |
| 650 | 4 | |a Severe haemophilia A | |
| 650 | 4 | |a Émicizumab | |
| 650 | 7 | |a Antibodies, Bispecific |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a emicizumab |2 NLM | |
| 650 | 7 | |a 7NL2E3F6K3 |2 NLM | |
| 700 | 1 | |a Pieragostini, R |e verfasserin |4 aut | |
| 700 | 1 | |a Roussel-Robert, V |e verfasserin |4 aut | |
| 700 | 1 | |a Paubel, P |e verfasserin |4 aut | |
| 700 | 1 | |a Degrassat-Theas, A |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez, I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annales pharmaceutiques francaises |d 1945 |g 81(2023), 3 vom: 01. Mai, Seite 529-537 |w (DE-627)NLM000046493 |x 0003-4509 |7 nnns |
| 773 | 1 | 8 | |g volume:81 |g year:2023 |g number:3 |g day:01 |g month:05 |g pages:529-537 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pharma.2022.11.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 81 |j 2023 |e 3 |b 01 |c 05 |h 529-537 | ||